Clinical Trials

868 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06345729 2026-05-26

KANDLELIT-004

600 enrolled

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06607185 2026-05-26

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

750 enrolled

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT06731907 2026-05-26

MK-3475-01G

90 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06788912 2026-05-26

MK-3475-01E

60 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT07190248 2026-05-26

KANDLELIT-007

675 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07221474 2026-05-26

INTerpath-13

180 enrolled

Squamous Non-small Cell Lung Cancer

NCT07353957 2026-05-26

Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer

180 enrolled

Lung Neoplasms

NCT03412877 2026-05-22

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

BreastEndocrineGynecologicNETPlasma cellThoracic

285 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Multiple Myeloma, Ovarian Neoplasms, Urogenital Neoplasms, Neuroendocrine Tumors

NCT05920356 2026-05-22

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

750 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06170788 2026-05-22

TroFuse-007

614 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06312137 2026-05-22

TroFuse-019

780 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06422143 2026-05-22

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

851 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06627647 2026-05-22

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

878 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT06704724 2026-05-22

A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.

Phase 1 Terminated

30 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Pancreatic Ductal

NCT06712316 2026-05-22

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

1,260 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung

NCT06789172 2026-05-22

INVOKE

Phase 1 Recruiting

166 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Liposarcoma, Sarcoma, Colorectal Neoplasms, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous, Solitary Fibrous Tumors

NCT04613596 2026-05-20

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

626 enrolled

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05537740 2026-05-20

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

129 enrolled

BreastDermatologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Recurrence, Triple Negative Breast Neoplasms

NCT06561386 2026-05-20

RELATIVITY1093

1,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07222566 2026-05-20

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

1,410 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT07365319 2026-05-20

TeLuRide-008

750 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05431270 2026-05-19

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

Phase 1/2 Recruiting

40 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT06119581 2026-05-19

SUNRAY-01

1,264 enrolled

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT06890598 2026-05-19

SUNRAY-02

700 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT07486817 2026-05-19

Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab

60 enrolled

Phase 2 Active not recruiting

Lung Neoplasms

NCT04032418 2026-05-18

Pembrolizumab Every 12 Weeks Versus Every 3 Weeks in Treating Patients With Non-small Cell Lung Cancer

9 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04165070 2026-05-18

MK-3475-01A

Phase 1/2 Recruiting

450 enrolled

Phase 2/3 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05096663 2026-05-18

Testing the Use of Combination Immunotherapy Treatment (N-803 [ALT-803] Plus Pembrolizumab) Against the Usual Treatment for Advanced Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)

82 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05789082 2026-05-18

KRAScendo 170

Phase 1/2 Recruiting

320 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06357533 2026-05-18

TROPION-Lung10

675 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06452277 2026-05-18

SOHO-02

444 enrolled

Advanced Non-small Cell Lung Cancer

NCT07063745 2026-05-18

MountainTAP-29

590 enrolled

Lung Neoplasms

NCT07394062 2026-05-18

ALCG-01

Recruiting

400 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02444741 2026-05-15

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

Phase 1/2 Completed

124 enrolled 15 charts

DermatologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Terminated

225 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT04380636 2026-05-15

MK-7339-012

Phase 3 Active not recruiting

870 enrolled

Phase 1 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04526691 2026-05-15

Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)

145 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06623422 2026-05-15

INTerpath-009

680 enrolled